Job title: Senior Vice President, R&D Pharmacology & Co-founder
Sophie Bozec joined Merck KGaA in 1998 where she managed a drug discovery team in a pharmacology department. Dr. Bozec has acquired a strong experience for managing research projects from target identification to preclinical development candidates. She has developed her knowledge in models (in vivo and in vitro) used in research programs for identifying preclinical development candidates in the diabetes field. She acquired a solid expertise in metabolic diseases particularly in the diabetes and NASH fields. This experience in pharmacology led Dr. Bozec to support a clinical development compound for all preclinical pharmacology aspects. Dr Bozec is one of Poxel Co-founders and is managing pharmacology activities. Dr. Bozec holds a PhD in Nutrition, Metabolism and Obesity from the Paris VII University.
Clinical Stage Molecules Targeting Mitochondrial Mechanisms & Mitochondrial Dysfunction for Metabolic Disorders 11:30 am
• Understand mitochondrial dysfunction in metabolic diseases • Examine how Imeglimin; a new first in class acts on Mitochondrial bioenergetics as a new treatment for Type 2 diabetes • Explore PXL065 a stabilized single stereoisomer of pioglitazone acts on a mitochondrial target to enable treatment of NASH • Observe PXL770, a direct AMPK activator ameliorates…Read more
day: Day Two